Hangzhou Jiuyuan Genetic Engineering has filed for an IPO on the Hong Kong Exchange to develop its portfolio of biopharmaceutical products and medical devices. Founded in 1993, the company has two major products: a drug-device combination product, Guyoudao, the first product containing bone repair material with rhBMP-2 that is approved for China use, and the first semaglutide biosimilar in China to have filed an NDA. Semaglutide is a Novo Nordisk GLP-1 product known as Wegovy for weight loss and Ozempic for type 2 diabetes. More details....

Share this with colleagues:  

Innovent Biologics announced a strategic partnership with Beijing’s WeComput to advance its AI based platform for drug development. WeComput will work with Innovent Academy, the company’s division that “thinks big” about future drug development and has already developed an AI platform. Innovent Academy will use WeComput's WeMol, a molecular design platform, to extend its computing infrastructure, accelerating R&D. WeMol will integrate NVIDIA's BioNeMo to expand the computing capacity of Innovent's AI systems and improve computational efficiency. WeComput is a subsidiary of Beijing Zhongda Weixin Technology, an IT company. Innovent is a Suzhou biopharma with additional R&D operations in Shanghai and San Francisco. More details....

Share this with colleagues:  

BeiGene officially opened a $800 million flagship US facility that houses state-of-the-art biologics manufacturing capabilities and a clinical R&D center. BeiGene, an oncology company that got its start in Beijing, now considers itself a global company with additional headquarters in Boston and Basel. The company is proud of the fact that it conducts its own clinical trials, largely free of CROs, which it says improves speed, cost and quality. The new facility is located in Hopewell, NJ, at the Princeton West Innovation Campus. BeiGene is developing an oncology portfolio of more than 30 molecules at clinical or commercial stage. More details....

Share this with colleagues:  

Xiamen Amoytop Biotech will conduct a clinical trial of its approved HBV therapy, Pegbing®, together with a clinical stage HBV therapy developed by Aligos Therapeutics, a South San Francisco biopharma. Aligos’ ALG-000184 is a potentially best/first-in-class oral small molecule capsid assembly modulator (CAM-E) aimed at CHB. Amoytop will conduct a China Phase 1b trial that tests the efficacy and safety of ALG-000184 in combination with its own Pegbing® (Mipeginterferon alfa-2b). Three months ago, the two companies entered a $109 million pact to use Aligos' platform for discovery of oligonucleotides that treat liver diseases. More details....

Share this with colleagues:  

Nanjing Triastek, a company that uses 3D printing to manufacture pharmaceuticals, will develop oral RNA therapeutics with Germany’s BioNTech based on its 3D printing technology. Triastek will receive a $10 million upfront payment and up to $1.2 billion in milestones, plus royalties. Triastek uses its 3D technology to improve delivery of RNA therapeutics across the gastrointestinal mucosa, minimizing premature degradation and delivering RNA therapeutics to the gastrointestinal track areas with the greatest absorption. The collaboration aims to provide groundbreaking therapies that address unmet medical needs in an easy-to-administer oral formulation. More details....

Share this with colleagues: